Business
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":" ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate Responses Similar to Approved Autologous CAR T Therapy ALLO-715 Was Well Tolerated with No Graft-vs-Host Disease and Manageable Safety71% Overall Response Rate (ORR) with FCA Lymphodepletion 46% Achieved a Very Good Partial Response or Better (VGPR+) Including 25% Complete Response or Stringent Complete Response (CR/sCR)92% of Patients with VGPR+ Were Minimal Residual Disease (MRD) NegativeMedian Duration of Response was 8.3 months Study Highlights the Ability to Initiate AlloCAR T Therapy within Five Days of Enrollment with No Bridging TherapyCompany to Host a Conference Call and Webcast Today, Monday, December 13, at 1:30 p.m. PT/4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced positive updated results from the Phase 1 UNIVERSAL study of single dose ALLO-715 in relapsed/refractory (r/r) multiple myeloma. Data were presented today in an oral session by Sham Mailankody, MBBS, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center in New York, during the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta. This study utilizes ALLO-647, Allogene's anti-CD52 monoclonal antibody, as a part of its differentiated lymphodepletion (LD) regimen. “UNIVERSAL is the first study of an allogeneic anti-BCMA CAR T to demonstrate safety and substantial efficacy in patients with relapsed-refractory multiple myeloma,” said Dr. Mailankody. “Safety, response and durability are on par with the approved autologous CAR T therapy and appear to be superior to other readily available therapies for multiple myeloma. This is especially encouraging given the high percentage of penta-refractory patients enrolled in the study. The data validates the feasibility of ALLO-715 as an allogeneic, on demand CAR T product that may be an option for patients with rapidly progressing disease and limited treatment options.” “We are encouraged by these updated findings from the UNIVERSAL study that show a single dose of an off-the-shelf AlloCAR T product is capable of inducing deep...